Sofetabart Mipitecan

Phase 3Small molecule

Eli Lilly

Sofetabart Mipitecan is one of 41 small molecule programs targeting Ovarian Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerActive, not recruiting

Ovarian NeoplasmsRecruiting

Ovarian CancerPhase 3

Active, not recruiting

Ovarian NeoplasmsPhase 3

Recruiting

Competition

Competitive Landscape

836 competitors in Ovarian Cancer

#DrugCompanyPhaseTrials

Hycamtin

MMeitheal

Phase 3

28 2

Perjeta

Roche

Phase 3

3 3

Aromasin

Pfizer

Phase 3

2 4

Bavencio

EMD Serono

Phase 3

7 5

Sacituzumab Tirumotecan

Merck & Co.

Phase 3

1 6

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

4 7

Doxorubicin HCL Liposome

AAccelerated Community Oncology Research Network

Phase 3

2 8

In Vitro Sensitivity-Directed Chemotherapy

CChildren's Oncology Group

Phase 3

1 9

Sofetabart Mipitecan

Eli Lilly

Phase 3

1 10

Long-Acting G-CSF

LLei Li

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 3Recruiting

Ovarian Neoplasms

NCT07213804

Clinical

Trials by Indication[1]

Ovarian Neoplasms1 trial

FRAmework-01: A Three-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) Versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan Plus Bevacizumab Versus Platinum-Based Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer.

Recruiting· Eli Lilly logo

Eli Lilly·Phase 3·NCT07213804·1,630 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sofetabart Mipitecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sofetabart Mipitecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sofetabart Mipitecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Eli Lilly

Sofetabart Mipitecan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Ovarian Neoplasms1 trial

References

Drug Info

Quick Facts

Related News